Oxford University Press, OxfordCrossRef FitzGerald GA (2009) Movi

Oxford University Press, OxfordCrossRef FitzGerald GA (2009) Moving clinical

research in academic medical centres up the value chain. Nat Rev Drug Discov 8:597CrossRef Food and Drug Administration (FDA) (2004) Innovation or stagnation. Challenge and opportunity on the critical path to new medical products. U.S. Department of Health and Human Services, Washington, D.C Gaisser S, Vignola-Gagné E, Hüsing B, Enzing C, van der Valk T (2009) EU policies in personalized medicine-related technologies. Personalized Med 6(1):93–102CrossRef Gottweis H (1998) Governing molecules. MIT press, Cambridge (Massachusetts) and London Grimaldi R, Kenney M, Siegel DS, Wright M (2011) 30 years after Bayh-Dole: reassessing academic entrepreneurship. Res Policy 40(8):1045–1057CrossRef Guston DH (2000) GSK126 concentration Between

politics and science. Cambridge University Press, CambridgeCrossRef Hakkinen U, Lehto J (2005) Reform, change and continuity Angiogenesis inhibitor in Finnish health care. J Health Polit Policy Law 30(1-2):79–96PubMedCrossRef Harrigan RS, Emery LM (2010) Translational leadership: new approaches to team development. Ethn Dis 20: S1-141-S1-145. Hoelder S, Clarke PA, Workman P (2012) Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 6:155–176PubMedCrossRef Hörig H, Marincola E, Marincola MF (2005) Obstacles and opportunities in translational research. Nat Med 11:705–708PubMedCrossRef Adenosine Institute of Medicine (2009) In: Sarah H, Lori N, Bruce Altevogt R (eds) Venture philanthropy

strategies to support translational research: workshop summary. The National Academies Press, Washington, DC Janssens ACJW, van Duijn CM (2010) An epidemiological perspective on the future of direct-to-consumer personal genome testing. Investig Genet 1(1):10PubMedCrossRef Keating P, Cambrosio A (2012) Cancer on trial. Oncology as a new style of practice. University of Chicago Press, Chicago Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L (2007) The continuum of translational research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9(10):665–674PubMedCrossRef Kupferschmidt K (2011) Germany clambers aboard translational research bandwagon. Can Med Assoc J 183:E219–E220CrossRef Lander B, Atkinson-Grosjean J (2011) Translational science and the hidden research system in universities and academic hospitals: a case study. Soc Sci Med 72:537–544PubMedCrossRef MacIlwain C (2011) Pharmaceutical industry must take its medicine. Nature 470:141PubMedCrossRef Marincola FM (2011) The trouble with translational medicine. J Intern Med 270:123–127PubMedCrossRef Martin P, Hopkins MM, Nightingale P, Kraft A (2009) On a critical path: genomics, the crisis of pharmaceutical productivity and the search for sustainability. In: Atkinson P, Glasner P, Lock M (eds) Handbook of genetics and society.

Related posts:

  1. , 1991, Terrosi et al , 2009 and Valassina et

    al , 2003),
  2. , 1995; Rosenberg et al , 2009; Hallmayer et al , 2011) Yet, due
  3. NIH Launches Web Resource on Complementary and Alternative Medicine
  4. 2009 Director’s Testimony
  5. The recent drops in preterm birth rates in the United States may
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>